Orbimed Advisors - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2021$68,580,000
-18.4%
612,700
+18.1%
0.75%
-11.3%
Q2 2021$84,021,000
+24.8%
519,000
-6.1%
0.85%
+35.1%
Q1 2021$67,322,000
-2.7%
552,500
+22.3%
0.63%
+4.0%
Q4 2020$69,175,000
+31.3%
451,800
-28.3%
0.60%
-8.6%
Q3 2020$52,694,000
+2.8%
630,004
-9.7%
0.66%
-8.3%
Q2 2020$51,261,000
+119.3%
697,524
+26.5%
0.72%
+83.7%
Q1 2020$23,376,000
-49.9%
551,200
-28.1%
0.39%
-41.0%
Q4 2019$46,676,000
+120.5%
766,378
+48.4%
0.67%
+65.7%
Q3 2019$21,167,000
-3.8%
516,400
+4.1%
0.40%
+51.7%
Q3 2018$22,006,000
-24.5%
496,2000.0%0.26%
-23.9%
Q2 2018$29,157,000
+511.0%
496,200
+375.3%
0.35%
+489.8%
Q1 2018$4,772,000
-28.3%
104,401
-71.9%
0.06%
-7.8%
Q3 2017$6,651,000
+11.5%
372,1910.0%0.06%
+1.6%
Q2 2017$5,963,000
-26.4%
372,1910.0%0.06%
-31.5%
Q1 2017$8,103,000
+7.5%
372,1910.0%0.09%
-4.2%
Q4 2016$7,541,000372,1910.10%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2021
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders